Carboprost tromethamine injection enhanced the efficacy of focused ultrasound ablation surgery for hyperintense uterine fibroids: a retrospective study
To investigate whether carboprost tromethamine injection enhances the efficacy of focused ultrasound ablation surgery (FUAS) for hyperintense uterine fibroids (UFs) on T2-weighted MR imaging (MRI). In this single-center study, 112 patients with symptomatic UF In the carboprost tromethamine group, the non-perfused volume (NPV) ratio was 98.38% (IQR: 91.65 - 104.35%), the energy-efficiency factor (EEF) was 2.44 J/mm³ (IQR: 1.38 - 4.83 J/mm³), and the sonication time was 400.00 s (IQR: 205.00 - 605.00 s). However, in the oxytocin group, the NPV ratio was 81.76% (IQR: 59.67 - 89.66%), the EEF was 6.98 J/mm³ (IQR: 3.92 - 14.05 J/mm³), and the sonication time was 733.50 s (295.00 - 1127.50 s). Statistically significant differences in NPV ratio, EEF, and sonication time between the two groups were observed. When FUAS was performed on UFs with 3 - 4 levels of blood flow, there were significant differences between the two groups ( Compared with oxytocin, carboprost tromethamine injection significantly reduced the energy for ablating UFS with FUAS, thereby enhancing treatment efficiency. this strategy provides a new option for patients with hyperintense fibroids and grade 3-4 blood flow in fibroids.